Laboratoires Servier
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
 |
|
| Private | |
| Industry | Pharmaceutical |
| Founded | (1954) |
| Founder | Jacques Servier |
| Headquarters | Suresnes, France |
| Products | Pharmaceuticals |
| Revenue | €3.9 billion (FY 2015) |
|
Number of employees
|
21,200 |
| Website | Official website |
| Footnotes / references [1][2] |
|
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression.[3] The consolidated turnover for the 2015 financial year was €3.9 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 140 countries, achieving 82% of its sales outside France.[3] The annual sales of its ACE inhibitor, Coversyl (perindopril), in 2006 and 2007 exceeded 1 billion US dollars, making it Servier's highest-selling product.[citation needed]
The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 21,200 employees worldwide. The company's production sites produced 853 million drug boxes in 2013.[3]
The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[4] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5]
Product portfolio
Notable products:
- Gliclazide (Diamicron, Diamicron MR) — antidiabetic drug
- Indapamide (Fludex SR, Natrilex SR, Lozide) — diuretic
- Ivabradine (Procoralan) — antianginal drugs
- Perindopril (Coversyl) — ACE inhibitor
- Strontium ranelate (Protelos) — osteoporosis agent
- Tianeptine (Stablon) — antidepressant, indirect alteration of AMPA and NMDA glutamate receptor activity
- Trimetazidine (Vastarel MR) — antianginal drug.[6]
Other products:
- Agomelatine (Valdoxan, Melitor, Thymanax)
- Almitrine (Duxil, Vectarion)
- Amineptine (Survector, Maneon, Directim)
- Benfluorex (Mediaxal)
- Carbutamide (Glucidoral)
- Daflon 500
- Fenspiride (Pneumorel)
- Fotemustine (Muphoran)
- Fusafungine (Locabiotal)
- Gliclazide (Diamicron)
- Indapamide (Natrilix, Tertensif, Lozide)
- Perindopril (Coversyl, Prestarium)
- Perindopril/indapamide (Preterax, Coversyl Plus)
- Piribedil (Trivastal retard)
- Rilmenidine (Hyperium)
- Sodium alginate (Pseudophage)
- Sulbutiamine (Arcalion)
- Tertatolol (Artex)
- Vitamins (Vitathion)
Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[7][8] Further investigations found that many previous safety alerts on that drug had been either missed or hushed down, possibly through improper influence of the company.[8]
Collaborative research
As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[9][10] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[11]
In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:
- In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)
- In Diabetes: INTARCIA (USA, 2014)
- In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), GENFIT (FR, 2004)
- In Neurology (MS): GENEURO (CH, 2014)
- In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)
- In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010)
- In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 3.0 3.1 3.2 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Article of the Figaro about Mediator
- ↑ 8.0 8.1 Un doute sur la «sécurité» du Mediator dès 1998 - Libération
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.[dead link]
